Jillian Gately is a member of Choate’s IP Litigation Group. Jillian represents a broad range of clients, including in the pharmaceutical, biotechnology and technology industries, involved in intellectual property matters as well as complex commercial disputes. Jillian also has experience assisting clients in internal investigations and in conducting pre-litigation analyses.
Jillian recently served as a Special Assistant District Attorney with the Suffolk County District Attorney’s Office, where she gained significant criminal trial – both jury and bench – and motion practice experience.
- Counsel for former owners of a radiopharmaceutical company in a contract action in the Southern District of New York.
- Counsel for semiconductor manufacturer in a contract action in the District of Massachusetts.
- Represented patent holder biopharmaceutical company in a patent infringement litigation related to the compositions and methods for treatment of a rare genetic disorder.
- Represented software company in a contract and non-competition action related to an asset purchase agreement.
- Represented individual through the Lawyer’s Clearinghouse’s Legal Clinic in social security hearing presided over by an Administrative Law Judge.
Professional and Community Involvement
- Member of the Wesleyan Athletics Advisory Counsel where she has spoken on a few “Young Alumni” panels for current Wesleyan athletes
Education & Credentials
- Boston College Law School
- JD, 2018, cum laude
- Executive Editor, Uniform Commercial Code Reporter-Digest
- Wesleyan University
- BA, 2015
Key takeaways compiled by Choate attorneys who recently participated in the IPWatchdog Life Sciences Masters, which provided insights on the latest updates and trends in intellectual property law and the biopharmaceutical industry.
Choate and Anita Spieth are noted in Law360’s article, “Individual Inventors Face Rough Day At Federal Circuit,” regarding a three-judge panel’s non-precedential opinion in Shamoon v. Resideo Technologies Inc. The Federal Circuit upheld the PTAB's decision to invalidate an inventor’s patent claims related to wireless communications.
On March 27, the U.S. Supreme Court heard arguments in Amgen v. Sanofi et al, No. 21-757, one of this term’s most highly-watched cases concerning the law of enablement as it applies to patents directed to antibody therapeutics. Choate’s amicus brief, submitted on behalf of Nobel Prize laureate Sir Gregory Paul Winter and other interested scientists in support of Sanofi and Regeneron, was repeatedly highlighted by counsel during the argument.
On February 10, 2023, Choate submitted an amicus brief to the U.S. Supreme Court on behalf of Sir Gregory Paul Winter and other interested scientists in support of Sanofi and Regeneron in Amgen v. Sanofi et al, No. 21-757. The case involves the law of enablement for patents and whether the Federal Circuit Court of Appeals correctly interpreted the law when it invalidated Amgen’s patents directed to broad classes of antibody drugs called PCSK9 inhibitors.